Trial Profile

A Phase 1 Study Of SU011248 [sunitinib; Sutent] And Gemcitabine [Gemzar] In Patients With Advanced Solid Tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 May 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Sunitinib (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Pfizer

Most Recent Events

20 May 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
20 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
18 Apr 2009 Planned end date changed from 1 Sep 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com